iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment

Bioengineering, Journal Year: 2025, Volume and Issue: 12(1), P. 60 - 60

Published: Jan. 13, 2025

Chimeric Antigen Receptor (CAR)-engineered T (CAR-T) cell therapy represents a highly promising modality within the domain of cancer treatment. CAR-T has demonstrated notable efficacy in treatment hematological malignancies, solid tumors, and various infectious diseases. However, current is autologous, which presents challenges related to high costs, time-consuming manufacturing processes, necessity for careful patient selection. A potential resolution this restriction could be found by synergizing technology with induced pluripotent stem (iPSC) technology. iPSC inherent capability furnish an inexhaustible reservoir resources. Experimental evidence successful generation human cells using technology, showcasing yield, purity, robustness, tumor-killing efficacy. Importantly, enables production clinical-grade cells, significantly reducing costs time, facilitating their use as allogeneic therapies treat multiple patients simultaneously. In review, we aim elucidate essential facets therapy, delineate its utility, enumerate advantages drawbacks, offer in-depth evaluation novel pragmatic approach

Language: Английский

The clinical landscape of CAR-engineered unconventional T cells

Trends in cancer, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Unconventional T cells, such as invariant natural killer (iNKT), γδ T, and mucosal-associated (MAIT) play a pivotal role in bridging innate adaptive immunity. Their capacity for rapid tumor targeting effective modulation of the microenvironment (TME) makes them promising candidates cancer immunotherapy. Advances chimeric antigen receptor (CAR) engineering have further highlighted their therapeutic potential, particularly treating challenging cancers. Notably, these cells exhibit favorable safety profiles, enhancing viability off-the-shelf options. We provide comprehensive analysis clinical applications CAR-engineered unconventional focusing on genetic modifications, manufacturing processes, preconditioning regimens, dosing strategies. discuss successful examples from recent trials explore future directions utilizing therapy beyond.

Language: Английский

The microbiota shapes the life trajectory of mucosal-associated invariant T cells

Trends in Microbiology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский